Presentation at Digestive Disease Week 2021 on a novel, gut-selective small molecule Bcl2 inhibitor designed to reduce or reverse intestinal fibrosis. Compound design, selection, pharmacokinetics, in vitro activity, and in vivo testing in a mouse model are described. This is a promising first step in developing anti-fibrotic drugs for Crohn's disease, though these results are currently limited to mouse models, which has low predictive value for eventual success in human therapy.